Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Physical Gold ETF (AAAU) vs Eli Lilly And Co (LLY) Price & Performance

Goldman Sachs Physical Gold ETF
Eli Lilly And Co

Price performance

Price movement over the last 24 hours

Key statistics

Goldman Sachs Physical Gold ETF vs Eli Lilly And Co — how do they compare? Goldman Sachs Physical Gold ETF trades at $40.11, while Eli Lilly And Co trades at $1,223 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while Goldman Sachs Physical Gold ETF pays none. Which is the better fit depends on your goals.

AAAULLY
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$53.21$1.24K
52-Week Low
$32.29$625.65
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Physical Gold ETF

AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.

Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.

The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goldman Sachs Physical Gold ETF

AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.

Read more on AAAU

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY